Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations

View ORCID ProfileSara Khanal, Megan Webster, Naiqian Niu, Myra Nunez, Geoffrey Chupp, Martin D. Slade, Lauren Cohn, Maor Sauler, Jose L. Gomez, Robert Tarran, View ORCID ProfileLokesh Sharma, Charles S. Dela Cruz, Marie Egan, View ORCID ProfileTheresa Laguna, View ORCID ProfileClemente J. Britto
doi: https://doi.org/10.1101/2020.05.15.20100669
Sara Khanal
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara Khanal
Megan Webster
2Department of Cell Biology & Physiology University of North Carolina Chapel Hill, North Carolina 27599
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naiqian Niu
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myra Nunez
4Division of Pediatric Respiratory Medicine University of Minnesota Minneapolis, Minnesota 55454
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Chupp
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin D. Slade
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Cohn
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maor Sauler
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose L. Gomez
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tarran
2Department of Cell Biology & Physiology University of North Carolina Chapel Hill, North Carolina 27599
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lokesh Sharma
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lokesh Sharma
Charles S. Dela Cruz
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Egan
3Division of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Laguna
4Division of Pediatric Respiratory Medicine University of Minnesota Minneapolis, Minnesota 55454
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Theresa Laguna
Clemente J. Britto
1Section of Pulmonary, Critical Care and Sleep Medicine Yale University School of Medicine New Haven, Connecticut 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clemente J. Britto
  • For correspondence: clemente.britto@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Acute pulmonary Exacerbations (AE) are episodes of clinical worsening in cystic fibrosis (CF), often precipitated by infection. Timely detection is critical to minimize the morbidity and lung function decline associated with acute inflammation during AE. We previously demonstrated that the airway protein Short Palate Lung Nasal epithelium Clone 1 (SPLUNC1) is regulated by inflammatory signals. Here, we investigated the use of SPLUNC1 fluctuations to diagnose and predict AE in CF.

We enrolled adult CF subjects from two independent cohorts to measure AE markers of inflammation in sputum and recorded clinical outcomes for a 1-year follow-up period.

SPLUNC1 levels were high in healthy control sputum (n=9, 10.7μg/mL), and significantly decreased in CF subjects without AE (n=30, 5.7μg/mL, p=0.016). SPLUNC1 levels were 71.9% lower during AE (n=14, 1.6μg/mL, p=0.0034) regardless of age, sex, CF-causing mutation, or microbiology findings. Cytokines Il–1β and TNFα were also increased in AE,whereas lung function did not consistently decrease. Stable CF subjects with lower SPLUNC1 levels were much more likely to have an AE at 60 days (Hazard Ratio: 11.49, Standard Error: 0.83, p=0.0033). Low-SPLUNC1 stable subjects remained at higher AE risk even one year after sputum collection (Hazard Ratio: 3.21, Standard Error: 0.47,p=0.0125). SPLUNC1 was transcriptionally downregulated by inflammatory cytokines and degraded by proteases increased in sputum during AE.

Our findings suggest that low sputum SPLUNC1 levels could detect subjects at increased risk of AE in order to guide early therapeutic interventions in CF.

TAKE-HOME MESSAGE Sputum concentrations of the secreted airway protein SPLUNC1 decrease during CF exacerbations. Lower SPLUNC1 levels in stable subjects portend a significantly increased risk of exacerbation and could inform therapeutic interventions.

PLAIN LANGUAGE SUMMARY SPLUNC1 is an abundant host defense protein found in the respiratory tract that decreases with inflammation. Individuals with cystic fibrosis experiencing clinical worsening (exacerbation) have much lower levels of SPLUNC1 in their sputum. In stable cystic fibrosis patients, lower levels of SPLUNC1 may predict an upcoming respiratory illness. Therefore, SPLUNC1 may serve as a tool for early diagnosis and treatment of cystic fibrosis exacerbations.

Competing Interest Statement

-Dr. Tarran reports: from Eldec Pharmaceuticals, outside the submitted work; In addition, Dr. Tarran has a patent Peptide inhibitors of Ca2+ channels pending, a patent PEPTIDE INHIBITORS OF SODIUM CHANNELS with royalties paid, and a patent Regulation of sodium channels by PLUNC proteins with royalties paid. -Dr. Laguna reports grants from National Institutes of Health, grants from Cystic Fibrosis Foundation, other from Vertex Physician Advisory Board, outside the submitted work;. -Dr. Cohn reports other from Genentech, other from Novartis, other from Astra-zeneca, other from GlaxoSmithKline, other from Regeneron, other from Pieris, other from Sanofi, outside the submitted work;. -Dr. Chupp reports from Genentech, other from Astra Zeneca, other from Sanofi - Regeneron, other from GSK, other from TEVA, other from Boehringer-Ingelheim, other from Circassia, outside the submitted work;.

Clinical Trial

Our study is not registered as a clinical trial because this is an observational study. We are not testing potential treatments for Cystic Fibrosis (CF), rather we are developing clinical markers to identify people at risk of clinical worsening in CF.

Funding Statement

This work was supported by NIH R01-HL081160 and R21-AI083475 (LC), NIH T32-HL007778, NIH/NHLBI K01-HL125514-01, and Cystic Fibrosis Foundation’s Fifth Year Clinical Fellowship (CB), American Thoracic Society Foundation Unrestricted Research Award (CB), CF Foundation (RT); UK CF Trust (RT).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

data

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations
Sara Khanal, Megan Webster, Naiqian Niu, Myra Nunez, Geoffrey Chupp, Martin D. Slade, Lauren Cohn, Maor Sauler, Jose L. Gomez, Robert Tarran, Lokesh Sharma, Charles S. Dela Cruz, Marie Egan, Theresa Laguna, Clemente J. Britto
medRxiv 2020.05.15.20100669; doi: https://doi.org/10.1101/2020.05.15.20100669
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations
Sara Khanal, Megan Webster, Naiqian Niu, Myra Nunez, Geoffrey Chupp, Martin D. Slade, Lauren Cohn, Maor Sauler, Jose L. Gomez, Robert Tarran, Lokesh Sharma, Charles S. Dela Cruz, Marie Egan, Theresa Laguna, Clemente J. Britto
medRxiv 2020.05.15.20100669; doi: https://doi.org/10.1101/2020.05.15.20100669

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1103)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (504)
  • Epidemiology (9787)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2323)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11658)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (339)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2192)
  • Public and Global Health (4676)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)